1Mitsiades CS,Mitsiades N,Hideshima T,et al.Proteasome inhibition as a new therapeutic principle in hematological malignancies[J].Curr Drug Targets,2006,7(10):1341-1347.
2Adams J,Palombella VJ,Sausville EA,et al.Proteasome inhibitors:a novel class of potent and effective antitumor agents[J].Cancer Res,1999,59:2615-2622.
3Voorhees PM,Dees EC,Neil B,Orlowski RZ.The proteasome as a target for cancer therapy[J].Clin Cancer Res,2003,9:63166325.
4Hideshima T,Richardson P,Chauhan D,et al.The proteasome inhibitor PS-341 inhibits growth,induces apoptosis,and overcomes drug resistance in human multiple myeloma cells[J].Cancer Res,2001,61:3071-3076.
5Mitsiades N,Mitsiades CS,Poulaki V,et al.Molecular sequelae of proteasome inhibition in human multiple myeloma cells[J].Proc Natl Acad Sci USA,2002,99:14374-14379.
6Orlowski RZ,Stinchcombe TE,Mitchell BS,et al.Phase Ⅰ trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies[J].J Clin Oncol,2002,20:4420-4427.
7Richardson PG,Barlogie B,Berenson J,et al.Phase Ⅱ study of the Lightcap ES,McCormack TA,Pien CS et al.Proteasome inhibition measurements:clinical application[J].Clin Chem 2000;46:673 -683.
8Papandreou C,Daliani D,Millikan RE et al.Phase Ⅰ study of proteasome inhibitor PS-341 in multiple myeloma (MM) patients (pts) with relapsed/refractory disease[J].Proc Am Soc Clin Oncol (abstract 40),2002,(1):121-133.
9Blade J,Samson D,Reece D,et al.Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation[J].Br J Haematol,1998,102:1115-1123.
10Palmer M,Belch A,Brox L,Pollock E,Koch M.Are the current criteria for response useful for the management of multiple myeloma[J].J Clin Oncol,1987,5:1373-1377.
9Chen S,Gao J Halicka HD,et al.The cytostatic and cytotoxiceffects of oridonin,a diterpenoil from Rabdosia rubescens on tumorcells of different lineage[J].int J Oncol,2005,26:579-588.
